Quantcast

Garden State Times

Tuesday, April 22, 2025

FDA conducted second highest number of inspections on Biologics companies in New Jersey during Q1

Webp feai7bphhdls0aqws5mfv0zinhxh

Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website

Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA | Official Website

In the first quarter of 2025, six Biologics companies received six FDA inspections in New Jersey, according to the U.S. Food and Drug Administration (FDA).

This was the second highest number of inspections per type of company made by the FDA in New Jersey, equalling 12.2% of all inspections in the first quarter of 2025.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.

FDA Inspections in New Jersey During Q1
Project AreaNo Action IndicatedVoluntary Action IndicatedOfficial Action Indicated
Blood and Blood Products4
Compliance: Devices11
Drug Quality Assurance33
Food Composition, Standards, Labeling and Econ8
Foodborne Biological Hazards2661
Human Cellular, Tissue, and Gene Therapies2
Monitoring of Marketed Animal Drugs, Feed, and Devices11
Postmarket Assurance: Devices11
Technical Assistance: Food and Cosmetics1

MORE NEWS